Search Results
Feb 19, 2026, 08:00 ET Bausch Health's OraPharma Celebrates 25 Years of ARESTIN® (minocycline HCl) Microspheres
(NYSE:BHC)(TSX:BHC), and its dental products business, OraPharma, today announced the 25th anniversary milestone of ARESTIN® (minocycline HCl) Microspheres, 1 mg, a locally administered antibiotic used as an adjunct to scaling and root planing (SRP) for the reduction of pocket depth in adult patients with periodontitis.
More news about: Bausch Health Companies Inc.
Feb 19, 2026, 07:00 ET Insmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business Update
was 2.5%, 4.1%, and 4.0% in patients treated with placebo and BRINSUPRI 10 mg and 25 mg, respectively. Skin CancersIn ASPEN, the incidence of skin cancers among patients treated with BRINSUPRI 10 mg and 25 mg was 0.5% and 1.9%, respectively, compared to 1.1% in placebo-treated patients. AlopeciaIn
More news about: Insmed Incorporated
Feb 18, 2026, 19:40 ET Genicom to Showcase High-Temperature UV Sensor Solutions at AFPE 2026 in Shanghai
the event, Genicom will showcase the MG-12 Monitor / LO Probe Series, engineered to deliver reliable and stable UV measurement performance even in extreme industrial heat environments.GaN-Based Technology for High-Temperature ResilienceThe MG-12 Monitor / LO Probe Series incorporates
More news about: Genicom
Feb 18, 2026, 17:00 ET The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1
adults with DM1 for six months. Data were assessed from 38 participants who were randomized 3:1 to receive one dose of 1 mg/kg del-desiran, three doses of either 2 mg/kg del-desiran or 4 mg/kg del-desiran (reflected as siRNA dose), or placebo. The primary endpoint of the study was to evaluate the safety and
More news about: Avidity Biosciences, Inc.
Feb 18, 2026, 13:32 ET Kyowa Hakko Clarifies Glutathione Misconceptions with Science-Backed Insights on Quality and Efficacy of its Industry-Leading Setria® Brand
unmatched clinical backing. A six-month Penn State study, published in the European Journal of Nutrition, showed that daily doses of 250 mg or 1,000 mg increased glutathione levels by 30-35% in blood cells and 260% in buccal cells, with functional benefits including a doubling of natural killer
More news about: Kyowa Hakko U.S.A
Feb 18, 2026, 09:32 ET True Citrus Launches Innovative True Lemon Wellness Line for Cravings, Immunity and Energy Support
(120 mg of plant-based caffeine from green tea extract to help avoid crash or jitters, 200mg of L-Theanine, 200mg of GABA and 60mg magnesium to help support sustained focus, mental clarity and overall mood); Vitamin C (100% DV) to energize and support vitality, and 600mg of Balanced
More news about: True Citrus
Feb 18, 2026, 09:00 ET AVEO Oncology, an LG Chem company, Announces Completion of the First Interim Analysis in the Global Phase 3 FIERCE-HN Study
patients with HPV-negative recurrent or metastatic head and neck squamous cellcarcinoma (R/M HNSCC) –– 20mg/kg dose of ficlatuzumab selected for the combination arm officlatuzumab and cetuximab – – Trials in Progress poster
More news about: AVEO, an LG Chem company
Feb 18, 2026, 08:56 ET Bayou City Hemp Launches Funding Round to Fuel 200% Growth and Dominate $30B THC Beverage Boom with Retail Powerhouse Edge
Texas, Florida, Tennessee, and Illinois while turning regulatory challenges into opportunities."The impending federal amendments, setting a 0.4mg total THC per container limit effective November 2026, restrict many intoxicating hemp products, but BCH is positioned as a compliant leader collaborating
More news about: Bayou City Hemp Company
Feb 18, 2026, 07:30 ET RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer
immunotherapy. Patients with prior anti-EGFR therapy were excluded. RYBREVANT FASPRO™ was administered every three weeks (Q3W) at 2400 mg, or 3360 mg for patients weighing 80 kg or more. The primary endpoint is overall response rate (ORR) assessed by blinded independent central review (BICR)
More news about: Johnson & Johnson
Feb 18, 2026, 07:00 ET TopGum Brings Beauty-From-Within Supplementation to a Fruity Gummy
supplements.TopGum successfully combined meaningful doses of these two ingredients into a no-added-sugar gummy supplement. Each gummy contains 45mg hyaluronic acid and 200mg collagen peptides, nourishing the skin from within. The collagen is fish-derived, allowing for kosher certification with a neutral flavor
More news about: TopGum Industries, Inc.
Feb 18, 2026, 06:45 ET Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight
line at 1-800-222-1222 or go to the nearest hospital emergency room right away. Zepbound injection is approved as a 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL in single-dose pen or single-dose vial. Learn more Zepbound is a prescription medicine. For more
More news about: Eli Lilly and Company
Feb 17, 2026, 11:00 ET FDA Approves FILKRI™ (filgrastim-laha), Accord BioPharma's Biosimilar to NEUPOGEN® (filgrastim)
Stelara® (ustekinumab), HERCESSI™ (trastuzumab-strf), a biosimilar to Herceptin® (trastuzumab), and CAMCEVI® (leuprolide) 42 mg injectable emulsion.6,7 Please refer to the Important Safety Information and full Prescribing Information for these products, and to the Boxed
More news about: Accord BioPharma
Feb 17, 2026, 08:59 ET JYM Supplement Science Launches Creatine+, Its First-Ever Standalone Creatine Formula
creatine, including 4 grams of creatine monohydrate and 1 gram of NO3-T® creatine nitrate.In addition to contributing creatine, NO3-T® provides 500mg of nitrates, helping to enhance blood flow and muscle pumps, benefits not found in traditional standalone creatine monohydrate formulas. The result is
More news about: JYM Supplement Science
Feb 17, 2026, 07:45 ET TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers
The drug demonstrated a favorable safety profile even at the highest dose level of 1,000mg administered every two weeks. Based on pharmacokinetics and pharmacodynamics, the Company believes the optimal Phase 2 dose is 750mg every three weeks.About TuHURA Biosciences, Inc.TuHURA Biosciences,
More news about: TuHURA Biosciences, Inc.
Feb 16, 2026, 06:45 ET Lilly's Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer
Retevmo-related adverse reactions in patients with hepatic impairment.Retevmo (selpercatinib) is available as 40 mg and 80 mg capsules, and 40 mg, 80 mg, 120 mg, and 160 mg tablets.SE HCP ISI LA_NOV2025Please see full
More news about: Eli Lilly and Company
Feb 15, 2026, 15:21 ET Venturi's Strawberry Hibiscus Nitro Bold Brew Is The New Performance Ritual
bold.Introducing Strawberry Hibiscus, a nitro-infused cold brew that fuses coffee, tea, and fruit into a ready-to-drink can, delivering 192mg of clean, all-natural caffeine. It may be pretty in pink, but make no mistake, it's built to perform.In sports, contrast creates power. Speed
More news about: Venturi Bold Brew
Feb 13, 2026, 16:53 ET EUROPÄISCHE KOMMISSION GENEHMIGT UPLIZNA® VON AMGEN FÜR GENERALISIERTE MYASTHENIA GRAVIS
Reduzierung mit dem Ziel, bis Woche 24 eine Prednison-Dosis von 5 mg pro Tag zu erreichen. In Woche 26 hatten 87,4 % der Patienten, die UPLIZNA einnahmen, und 84,6 % der Patienten, die ein Placebo erhielten, ihre Steroiddosis auf 5 mg oder weniger pro Tag reduziert.5„UPLIZNA bietet
More news about: Amgen
Feb 13, 2026, 14:41 ET EURÓPSKA KOMISIA SCHVÁLILA LIEK UPLIZNA® OD SPOLOČNOSTI AMGEN NA LIEČBU GENERALIZOVANEJ MYASTÉNIE GRAVIS
Pacienti, ktorí dostávali steroidy na začiatku liečby, začali znižovať dávku v 4. týždni s cieľom dosiahnuť dávku 5 mg prednizónu denne do 24. týždňa. Do 26. týždňa znížilo dávku steroidov na 5 mg alebo menej denne 87,4 % pacientov užívajúcich liek UPLIZNA a 84,6 % pacientov užívajúcich placebo.5„Liek
More news about: Amgen
Feb 13, 2026, 11:47 ET ЕВРОПЕЙСКАЯ КОМИССИЯ ОДОБРИЛА ПРЕПАРАТ AMGEN UPLIZNA ® ДЛЯ ЛЕЧЕНИЯ ГЕНЕРАЛИЗОВАННОЙ МИАСТЕНИИ
заболевания II, III или IV по классификации Американского фонда миастении гравис (MGFA), балл по шкале MG-ADL от 6 до 10, причем более 50% этого балла относилось к невизуальным элементам, или балл по шкале MG-ADL по меньшей мере 11, и балл по количественной шкале миастении гравис (QMG) по меньшей мере 11.5 Участники
More news about: Amgen
Feb 13, 2026, 11:41 ET EVROPSKÁ KOMISE SCHVÁLILA PŘÍPRAVEK UPLIZNA® SPOLEČNOSTI AMGEN PRO GENERALIZOVANOU MYASTENII GRAVIS
začátku léčby dostávali steroidy, bylo ve 4. týdnu zahájeno snižování dávky s cílem dosáhnout do 24. týdne dávky prednisonu 5 mg denně. Do 26. týdne snížilo dávku steroidů na 5 mg nebo méně denně 87,4 % pacientů užívajících přípravek UPLIZNA a 84,6 % pacientů užívajících placebo.5„Přípravek
More news about: Amgen
Feb 13, 2026, 09:34 ET KOMISJA EUROPEJSKA ZATWIERDZA LEK UPLIZNA® FIRMY AMGEN W LECZENIU UOGÓLNIONEJ MIASTENII
redukcja rozpoczęto w 4. tygodniu, z celem zejścia do dawki prednizonu 5 mg na dobę do 24. tygodnia. Do 26. tygodnia 87,4% pacjentów przyjmujących UPLIZNĘ oraz 84,6% pacjentów otrzymujących placebo zmniejszyło dawkę sterydów do 5 mg na dobę lub mniej. [5]„UPLIZNA oferuje nową metodę leczenia
More news about: Amgen
Feb 13, 2026, 08:31 ET MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041
the 48 mg dose, we saw meaningful weight loss of about 9%, significant reductions in waist size, improvements in blood sugar levels, and early signs of direct liver benefit, all with a favorable safety profile."Mr. Kim continued, "Looking ahead, our planned 16-week titration studies to 48 mg and
More news about: MetaVia Inc.
Feb 13, 2026, 06:08 ET STADA and Bio-Thera receive European Marketing Authorization for Gotenfia, a Biosimilar to Simponi
package demonstrating that Gotenfia® is biosimilar to its reference product. The marketing authorization for Gotenfia® 50mg/0.5mL and 100mg/mL solution for injection in pre-filled syringes with passive needle safety guards applies across the 27 EU member states, in addition to Norway,
More news about: Bio-Thera Solutions, Ltd
Feb 12, 2026, 19:00 ET Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for First Line Treatment of HER2-positive Breast Cancer
6-15 mg/kg doses of IBI354.As of March 24, 2025, the overall confirmed objective response rate (cORR) was 59.1% and the disease control rate (DCR) was 90.9%.Among them, ORR reached 72.4% and DCR reached 89.7% in 29 breast cancer participants treated with 9mg/kg Q3W.The
More news about: Innovent Biologics
Feb 12, 2026, 15:30 ET LA COMMISSION EUROPEENNE APPROUVE UPLIZNA® D'AMGEN DANS LE CADRE DU TRAITEMENT DE LA MYASTHÉNIE GRAVE GÉNÉRALISÉE
diminuer leur dose à la semaine 4, l'objectif étant d'atteindre 5 mg de prednisone par jour à la semaine 24. À la semaine 26, 87,4 % des patients sous UPLIZNA et 84,6 % des patients sous placebo avaient réduit leur dose de stéroïdes à 5 mg ou moins par jour.5« UPLIZNA offre une nouvelle
More news about: Amgen